Rigel Pharmaceuticals Inc. failed to convince a federal judge that H2O isn’t water when another substance helps it deliver a drug’s active ingredient, part of a mixed ruling on disputed patent claims in a case over copies of the company’s most lucrative product.
Rigel alleged in the July 2022 lawsuit that a generic version of Tavalisse proposed by Hetero Labs Ltd.'s Annora Pharma unit infringes five patents for the drug, which is used to treat a chronic immune disease that leads to excessive bleeding. Judge Stanley R. Chesler’s opinion, issued Wednesday in the US District Court for ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.